# TARGET-D 201 (NCT07644559)

> A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07644559
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Verastem, Inc.
- Conditions: Pancreatic Ductal Adenocarcinoma (PDAC); G12D Mutated KRAS
- Interventions: VS-7375; cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)
- Enrollment: 185
- Primary outcome: Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1
- Primary outcome: To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab, administered on a daily oral schedule in participants with KRAS G12D-mutated PDAC.

## Indexed commentary on TARGET-D 201 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=target-d-201-nct07644559